Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal CancersFirst-in-class bi-specific antibody BI 905711 activates a pathway in TRAILR2 and CDH17 co-expressing tumor cells that leads to their destructionMay result in a more tolerable and selective therapy for patients affected with gastrointestinal cancers by avoiding liver toxicity commonly observed in other therapy approaches targeting TRAILR2Adds a promising candidate to Boehringer Ingelheim ’s multipronged oncology portfolio that combines cancer cell-directed and cancer immunology approaches to develop novel therapies for previously hard to treat cancers 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news